Method for inhibiting skin cell proliferation and/or anti-inflammation and method for treating skin diseases and/or inflammatory diseases

Abstract

A composition for inhibiting skin cell proliferation and/or anti-inflammation is provided. The composition for inhibiting skin cell proliferation and/or anti-inflammation includes: apigenin and luteolin, wherein a weight ratio of the apigenin to the luteolin is about 1.5-25:1, or a mole ratio of the apigenin to the luteolin is about 1.5-25:1. Moreover, the apigenin and the luteolin have a synergistic effect on inhibiting skin cell proliferation and/or anti-inflammation.

What is claimed is: 
     
         1 . A method for inhibiting skin cell proliferation and/or anti-inflammation, comprising:
 administering a skin cell proliferation inhibition and/or anti-inflammation pharmaceutical or health care composition to a subject in need thereof,   wherein the skin cell proliferation inhibition and/or anti-inflammation pharmaceutical or health care composition comprises:
 a combination of apigenin and luteolin as an active ingredient, 
 wherein the weight ratio of the apigenin to the luteolin is about 1.5-25:1 or the mole ratio of the apigenin to the luteolin is about 1.5-25:1, and the apigenin and the luteolin have a synergistic effect on anti-inflammation, or 
 wherein the weight ratio of the apigenin to the luteolin is about 1.5-15:1 or the mole ratio of the apigenin to the luteolin is about 1.5-15:1, and the apigenin and the luteolin have a synergistic effect on skin cell proliferation inhibition and/or anti-inflammation. 
   
     
     
         2 . The method for inhibiting skin cell proliferation and/or anti-inflammation as claimed in  claim 1 , wherein the skin cell comprises a keratinocyte or a skin fibroblast. 
     
     
         3 . The method for inhibiting skin cell proliferation and/or anti-inflammation as claimed in  claim 1 , wherein the inflammation comprises an inflammatory response involving macrophages. 
     
     
         4 . The method for inhibiting skin cell proliferation and/or anti-inflammation as claimed in  claim 1 , wherein the skin cell proliferation inhibition and/or anti-inflammation pharmaceutical or health care composition further comprises a pharmaceutically acceptable vehicle, carrier or salt. 
     
     
         5 . The method for inhibiting skin cell proliferation and/or anti-inflammation as claimed in  claim 4 , wherein a total content of the apigenin and the luteolin is about 0.1-20 wt %. 
     
     
         6 . The method for inhibiting skin cell proliferation and/or anti-inflammation as claimed in  claim 1 , wherein the skin cell proliferation inhibition and/or anti-inflammation pharmaceutical or health care composition is the skin cell proliferation inhibition and/or anti-inflammation pharmaceutical composition. 
     
     
         7 . The method for inhibiting skin cell proliferation and/or anti-inflammation as claimed in  claim 6 , wherein the skin cell proliferation inhibition and/or anti-inflammation pharmaceutical composition is a topical dosage form, wherein the topical dosage form comprises an ointment, a cream, a solution or a gel. 
     
     
         8 . A method for treating skin diseases and/or inflammatory diseases, comprising:
 administering a skin cell proliferation inhibition and/or anti-inflammation pharmaceutical or health care composition to a subject in need thereof,   wherein the skin cell proliferation inhibition and/or anti-inflammation pharmaceutical or health care composition comprises:
 a combination of apigenin and luteolin as an active ingredient, 
 wherein the weight ratio of the apigenin to the luteolin is about 1.5-25:1 or the mole ratio of the apigenin to the luteolin is about 1.5-25:1, and the apigenin and the luteolin have a synergistic effect on anti-inflammation, or 
 wherein the weight ratio of the apigenin to the luteolin is about 1.5-15:1 or the mole ratio of the apigenin to the luteolin is about 1.5-15:1, and the apigenin and the luteolin have a synergistic effect on skin cell proliferation inhibition and/or anti-inflammation. 
   
     
     
         9 . The method for treating skin diseases and/or inflammatory diseases as claimed in  claim 8 , wherein the skin disease comprises psoriasis or allergic or contact dermatitis.